Gossamer Bio Inc.已与Respira Therapeutics达成期权协议,计划收购该公司及其主要候选药物Rt234。Rt234是一款创新的按需吸入式伐地那非药物,专门用于治疗肺动脉高压。
Gossamer Bio Inc.已与Respira Therapeutics达成期权协议,计划收购该公司及其主要候选药物Rt234。Rt234是一款创新的按需吸入式伐地那非药物,专门用于治疗肺动脉高压。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.